HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:12/22/2014)... 22, 2014 TheHardwareCity.com now stocks MagnoGrip ... many useful features. Customers of the large online tool ... new gloves delivered to their home or workplace with ... tools that incorporate heavy duty magnets, which make work ... workers to store metal parts on the back of ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
(Date:12/22/2014)... Parker & Sons, Inc. a reliable ... home contracting services reports a record number of favorable ... in 2014. As a company that has served the ... and Sons is a business that is focused on ... with other top quality companies in Arizona that are ...
(Date:12/21/2014)... offers a wide range of women’s dresses, fashionable accessories ... BellasDress Christmas Sale , offering big discounts on all ... a famous online supplier of women’s dresses; it always ... promotions. The dress experts of the company provide professional ... of offering high quality wedding dresses and women’s special ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Hundreds ... product liability claims involving a class of Type ... to move forward in a federal multidistrict litigation ... of California, Bernstein Liebhard LLP reports. According to ... established a data cut-off date of February 27, ...
Breaking Medicine News(10 mins):Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
Cached News: